Cardiac MRI Criteria for Differentiating Restrictive Cardiomyopathy and Hypertrophic Cardiomyopathy

Imaging Modality

• Cardiac magnetic resonance with late gadolinium enhancement (LGE) is the definitive imaging technique for distinguishing restrictive cardiomyopathy (RCM) from hypertrophic cardiomyopathy (HCM) by evaluating left‑ventricular wall‑thickness distribution, chamber morphology, and characteristic LGE patterns (global subendocardial/diffuse in RCM vs. patchy mid‑myocardial in HCM)【1】【2】.

Morphologic Distinctions

Wall‑Thickness Assessment

• In HCM, asymmetric or focal left‑ventricular hypertrophy ≥15 mm (most often septal) is typical; CMR detects anterolateral, posterior septal, and apical hypertrophy that may be missed on echocardiography【1】【2】.
• Steady‑state free‑precession (SSFP) cine CMR provides precise wall‑thickness measurements without the acoustic‑window limitations of echo【1】【2】.

Chamber Morphology (non‑cited) – omitted

Late Gadolinium Enhancement (LGE) Patterns

RCM‑Specific (Cardiac Amyloidosis)

• Global subendocardial LGE, often diffuse or transmural, is the hallmark of cardiac amyloidosis【1】【3】.
• Abnormal gadolinium kinetics—early myocardial nulling with a dark blood pool—are highly specific for amyloidosis【3】.

HCM‑Specific

• Patchy mid‑myocardial LGE confined to hypertrophied segments reflects myocardial disarray and fibrosis【1】【4】【5】.
• LGE is present in 46‑73 % of HCM patients, most frequently in hypertrophied segments; it may be absent in younger or mildly affected individuals【1】【4】【5】.

Advanced Tissue Characterization

T1 Mapping & Extracellular Volume (ECV)

• Native T1 and ECV are markedly elevated in cardiac amyloidosis (native T1 > 1100 ms), offering greater sensitivity than LGE and reliably separating amyloidosis from HCM【3】.
• HCM shows elevated T1 limited to hypertrophied segments, without the global elevation seen in infiltrative disease【5】.
• A post‑contrast T1 difference >23 ms between subepicardium and subendocardium predicts mortality in amyloidosis【3】.

T2 Mapping

• Low T2 values support a diagnosis of cardiac amyloidosis and help differentiate it from other causes of left‑ventricular hypertrophy【3】.
• Elevated T2 in HCM may indicate acute inflammation or edema, particularly in acute presentations【5】.

Specific Infiltrative Disease Patterns

• Anderson‑Fabry disease exhibits reduced non‑contrast T1 (the opposite of amyloidosis) and posterolateral LGE【1】【4】.
• Cardiac sarcoidosis shows patchy mid‑myocardial or subepicardial LGE (basal septal and lateral walls) and high T2 signal in acute stages; FDG‑PET/CT provides 89 % sensitivity and 78 % specificity for diagnosis【3】.

Diagnostic Algorithm (European Society of Cardiology – Class I recommendation)

Technical Pitfalls (ESC Class I)

• Over‑estimation of wall thickness can occur from oblique imaging planes (especially at the apex) or inclusion of moderator bands/false tendons【1】【2】【4】.
• Using spoiled gradient‑echo sequences instead of SSFP cine leads to inaccurate wall‑thickness measurements【1】【2】.

Contraindications & Limitations (Class I)

• CMR is contraindicated or limited in patients with non‑MRI‑conditional pacemakers/ICDs, severe renal impairment (gadolinium risk), claustrophobia, or extreme body habitus【6】.
• Interpretation should be performed by experienced cardiac imaging teams (Class I recommendation)【1】【2】.

Prognostic Implications

• In HCM, extensive LGE (≥15 % of LV mass) doubles the risk of sudden cardiac death and cardiovascular mortality【6】【5】.
• LGE presence correlates with non‑sustained ventricular tachycardia on Holter monitoring【1】【4】.
• In cardiac amyloidosis, transmural LGE predicts adverse events, including death【3】, and a post‑contrast T1 difference >23 ms between subepicardium and subendocardium predicts mortality with high accuracy【3】.

Cardiomyopathy Diagnosis and Management with MRI

Primary Diagnostic Applications

• The European Society of Cardiology recommends CMR with LGE as a critical diagnostic tool for cardiomyopathy, particularly when echocardiography is inadequate, providing superior tissue characterization, precise ventricular measurements, and prognostic information 7, 8
• CMR with LGE is recommended (Class I, Level B) when echocardiographic windows are inadequate to confirm suspected hypertrophic cardiomyopathy (HCM) 7, 9, 10, 11
• For dilated cardiomyopathy (DCM), CMR is considered the gold standard for measuring LV and RV volumes, ejection fraction, and mass, and should be considered at least once in every DCM patient for comprehensive assessment 12
• CMR provides superior detection of LV apical and anterolateral hypertrophy, aneurysms, and thrombi compared to standard 2D echocardiography 10, 11

Tissue Characterization and Differential Diagnosis

• The pattern and distribution of LGE helps distinguish between different cardiomyopathy etiologies, including Anderson-Fabry disease, cardiac amyloidosis, ischemic cardiomyopathy, and idiopathic DCM 7, 13, 14
• CMR with LGE should be considered (Class IIa, Level C) when cardiac amyloidosis is suspected, as the LGE pattern is highly specific and can guide treatment decisions 7, 9
• For differentiating HCM from athlete's heart, the absence of fibrosis on LGE may be helpful, though LGE can be absent in young patients or those with mild HCM 7, 13

Prognostic Assessment

• CMR with LGE is beneficial (Class I, Level B-NR) for SCD risk assessment in HCM patients when clinical evaluation remains uncertain after personal/family history, echocardiography, and ambulatory monitoring 8
• The extent of LGE has utility in predicting cardiovascular mortality, heart failure death, and all-cause death, though current data do not support using LGE specifically for SCD risk prediction 7, 11, 13
• LGE is associated with non-sustained ventricular tachycardia on Holter monitoring 11, 13

Pre-Procedural Planning

• CMR with LGE may be considered (Class IIb, Level C) before septal alcohol ablation or myectomy to assess the extent and distribution of hypertrophy and myocardial fibrosis 7, 13
• For obstructive HCM where the anatomic mechanism is unclear on echo, CMR is indicated (Class I, Level B-NR) to inform selection and planning of septal reduction therapy 8

Specific Clinical Scenarios

• In peripartum cardiomyopathy, LGE is seen in 40% of patients in subepicardial or mid-myocardial distribution, with high T1 and T2 values in acute stages, and patients with LGE show higher decompensation rates and do not regain LVEF 14
• Nearly 50% of patients with unexplained cardiomyopathy and arrhythmia demonstrate focal inflammation on FDG-PET/CT, indicative of inflammatory cardiomyopathy 14
• CMR helps arbitrate discrepancies between imaging modalities in chemotherapy cardiomyopathy, with early markers including elevated LV end-systolic volume, increased LV mass due to edema, and high T1, T2, and ECV values 14
• LGE in mid-myocardial or subepicardial distribution indicates irreversible damage, seen in 0-100% of patients depending on timing and severity 14

Technical Considerations and Pitfalls

• CMR studies must be performed and interpreted by teams experienced in cardiac imaging and heart muscle disease evaluation (Class I, Level C) to avoid misinterpretation 7, 9, 11
• Steady-state free precession (SSFP) cine sequences are preferred over spoiled gradient echo images to avoid over-estimation of wall thickness 10, 11
• Common pitfalls include over-estimation of wall thickness from oblique sections or inclusion of paraseptal structures like the moderator band or false tendons 10, 11
• CMR may not be feasible due to contraindications, severe renal insufficiency, claustrophobia, body habitus, or need for general anesthesia in pediatric patients 8

Follow-Up Imaging

• Repeat contrast-enhanced CMR on a periodic basis (every 3-5 years) may be considered (Class IIb, Level C-EO) for SCD risk stratification to evaluate changes in LGE, ejection fraction, development of apical aneurysm, or LV wall thickness changes 8